Drug Target Review – Issue 1 2023
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
List view / Grid view
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
US researchers discover compound that limits weight gain in mice with a high-sugar diet, by lowering the mitochondrial magnesium.
US scientists suggest that anti-angiogenesis drugs could improve the function and delivery of CAR-T cell therapy.
By creating a drug that is based on part of the SARS-CoV-2 spike protein, US and Finnish researchers can block the virus from entering cells.
In this article Drug Target Review's Izzy Wood highlights three of the latest findings using lab automation techniques and technologies that aid scientists.
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.
Chronic pain often leads to depression, which US researchers have potentially solved using a mechanism involved with ketamine.
Researchers have found a potential therapeutic target less vulnerable to potential drug resistance and emerging COVID-19 variants of concern.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
A new drug could replace the current standard for treating radioresistance brain cancer by sensitising the cancer cells to radiotherapy.
US researchers outline the development of a new system for testing and developing CRISPR-based gene drives in the laboratory, and safely converting them into tools for potential real-world applications.
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
Research by University of Arkansas scientists into the binding affinity of potential drugs could help reduce the cost and time associated with developing new drugs.
US scientists have designed a mathematical model that can predict COVID-19 vaccines’ effectiveness over the long term in healthy individuals and those who have cancer or suppressed immune responses.